Loading…
Loading…
Base rate computed from analyst-asserted responds_to: edges in the reverse direction (target-country → issuer-country) for prior issuer-actions on the same target. Modal type + lag percentiles only — not a model output. Treat as a historical anchor for sizing counter-response scenarios, not a forecast in itself.
The 5 September 2024 BIS final rule layered four new ECCN categories onto the existing trilateral chip-equipment perimeter (filed: 2022-10-07-us-bis-advanced-ai-chip-controls-china, 2023-10-17-us-bis-advanced-chip-controls-expansion):
1. Quantum computing (3A901 + related ECCNs). Covers quantum computers above defined performance thresholds, the cryogenic + control + measurement systems required to operate them, and quantum-related software including error-correction implementations. 2. GAAFET production technology. The architectural successor to FinFET (Samsung 3nm, TSMC 2nm). Tools and know-how needed to manufacture GAAFET-architecture chips are now licence-controlled. This closes the "next-node" side of the chip-equipment perimeter that the Oct 2022 + Oct 2023 rules left open at the high-end. 3. Advanced additive manufacturing for metals. Equipment capable of producing high-performance metal/alloy components used in defence + aerospace + advanced semiconductor applications. 4. Biotech additions (parallel 12 September 2024 rule). Selected gene-synthesis + bioinformatics + dual-use research tools.
Multilateral framing is the meaningful innovation — the rule is structured to enable parallel adoption by Wassenaar Arrangement, Australia Group, and Nuclear Suppliers Group participants. This contrasts with the unilateral framing of the original Oct 2022 BIS package.
The original BIS controls covered ≤14/16nm logic, advanced DRAM, advanced 3D NAND. GAAFET is the architecture for ≤3nm logic — adding it to the licence regime keeps the perimeter ahead of the technology curve.
hit commercial scale, but the controls establish the regulatory framework before the market materialises — a proactive structural move rather than reactive.
biotech bilateral trade volumes with affected jurisdictions are small in dollar terms today; (b) multilateral framing means the unilateral disruption effect is diluted compared to the trilateral chip-equipment perimeter; (c) the rule doesn't impose end-use prohibitions of the BIS Oct-2022 type — it adds licensing requirements that are gated rather than blocking.
Quantum, Beijing Academy of Quantum Information Sciences): formalises the regulatory perimeter that had been informal before. Chinese firms face more difficult cryogenic + control-system sourcing.
controls reinforce TSMC/Samsung positions and the trilateral-perimeter durability through 2026.
Velo3D; European: EOS, GE Additive): export licensing for high-performance metal AM systems creates compliance friction but also competitive moat for cleared US/EU vendors.
controls hit certain Twist Bioscience-type business lines; the parallel 12 Sep 2024 rule deserves its own follow-up filing with full primary-source citation when verifiable.
it's the next-node + adjacent-tech extension of the original rule chain.
NSG coordination) is a structural shift versus the unilateral IEEPA/DPA pattern of the post-2024 US trade reset theme. The BIS lane and the IEEPA lane are operating in parallel with different constituencies + different durability profiles.
must individually update their domestic export-control lists to mirror BIS. Track Japan METI, Netherlands BHOS, EU individual member states for parallel rule-making in H2 2024 - 2025.
whether BIS keeps thresholds frozen or tightens them is the technology-cycle test.
2024-12) and 2025 (H20 cycle additions) trace the same perimeter-tightening pattern. File separately as primary sources cited.
This action backfills a charter §9 priority (#12 in priority list). BIS press release verified live; Federal Register link returned bot-challenge from the VPS but the URL pattern is canonical. CSIS + Reuters secondary citations preserved.